Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.bbrc.2020.10.042 http://scihub22266oqcxt.onion/10.1016/j.bbrc.2020.10.042 33341233!7577703!33341233     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33341233&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biochem+Biophys+Res+Commun 2021 ; 538 (ä): 163-172 Nephropedia Template TP {{tp|p=33341233|t=2021. The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?|pdf=|usr=}}{{33341233}} gab.com Text The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 JO: Biochem Biophys Res Commun http://www.kidney.de/pget.php?&tw=1&pmid=33341233 #FOAvip FDA approved for parasitic indications, the small molecule ivermectin has been the focus of growing attention in the last 8 years due to its potential as an antiviral. We first identified ivermectin in a high throughput compound library screen as an agent potently able to inhibit recognition of the nuclear localizing Human Immunodeficiency Virus-1 (HIV-1) integrase protein by the host importin (IMP) alpha/beta1 heterodimer, and recently demonstrated its ability to bind directly to IMPalpha to cause conformational changes that prevent its function in nuclear import of key viral as well as host proteins. Cell culture experiments have shown robust antiviral action towards a whole range of viruses, including HIV-1, dengue, Zika and West Nile Virus, Venezuelan equine encephalitis virus, Chikungunya, pseudorabies virus, adenovirus, and SARS-CoV-2 (COVID-19). Close to 70 clinical trials are currently in progress worldwide for SARS-CoV-2. Although few of these studies have been completed, the results that are available, as well as those from observational/retrospective studies, indicate clinical benefit. Here we discuss the case for ivermectin as a host-directed broad-spectrum antiviral agent, including for SARS-CoV-2. Twit Text FOAVip The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ????Biochem Biophys Res Commun http://www.kidney.de/pget.php?&tw=1&pmid=33341233 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33341233 #FOAvip English Wikipedia <ref>{{Cite pmid|33341233}}</ref> The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ? #MMPMID33341233 Jans DA; Wagstaff KM Biochem Biophys Res Commun 2021[Jan]; 538 (ä): 163-172 PMID33341233show ga FDA approved for parasitic indications, the small molecule ivermectin has been the focus of growing attention in the last 8 years due to its potential as an antiviral. We first identified ivermectin in a high throughput compound library screen as an agent potently able to inhibit recognition of the nuclear localizing Human Immunodeficiency Virus-1 (HIV-1) integrase protein by the host importin (IMP) alpha/beta1 heterodimer, and recently demonstrated its ability to bind directly to IMPalpha to cause conformational changes that prevent its function in nuclear import of key viral as well as host proteins. Cell culture experiments have shown robust antiviral action towards a whole range of viruses, including HIV-1, dengue, Zika and West Nile Virus, Venezuelan equine encephalitis virus, Chikungunya, pseudorabies virus, adenovirus, and SARS-CoV-2 (COVID-19). Close to 70 clinical trials are currently in progress worldwide for SARS-CoV-2. Although few of these studies have been completed, the results that are available, as well as those from observational/retrospective studies, indicate clinical benefit. Here we discuss the case for ivermectin as a host-directed broad-spectrum antiviral agent, including for SARS-CoV-2. |*COVID-19 Drug Treatment[MESH] |Antiparasitic Agents/*pharmacology/therapeutic use[MESH] |Antiviral Agents/*pharmacology/therapeutic use[MESH] |Humans[MESH] |Ivermectin/*pharmacology/therapeutic use[MESH] |SARS-CoV-2/*drug effects[MESH]The broad spectrum host-directed agent ivermectin as an antiviral for (epmc).pdf DeepDyve Pubget Overpricing